Imatinib Responsiveness in Canine Mast Cell Tumors Carrying Novel Mutationsof c-KIT Exon 11

Journal of Veterinary Medical Science

Yuko NAKANO¹  Yozo SHIRAISHI²  Masamine TAKANOSU²  Tetsushi YAMAGAMI²  Eri FUKAZAWA¹  Fukiko OSHIMA¹  Tetsuya KOBAYASHI¹ 

[1] Japan Small Animal Cancer Center, 2�?27�?4 Nakatomi-minami, Tokorozawa, Saitama 359�?0003, Japan;Japan Small Animal Medical Center, 2�?27�?4 Nakatomi-minami, Tokorozawa, Saitama 359�?0003, Japan

关键词: canine;    c-KIT;    imatinib mesylate;    mast cell tumor;    mutation;   

DOI  :  10.1292/jvms.13-0156

学科分类：兽医学

来源: Japanese Society of Veterinary Science

【 摘 要 】

References(11)Cited-By(4)In 2 individual cases ofcanine mast cell tumors, we identified 2 novel c-KIT mutations in exon11: a 9-base pair (bp) deletion (c.1663-1671del) and a point mutation (c.1676T>A). The9-bp deletion mutation caused a loss of 3 amino acids, corresponding top.Gln555_Lys557del, and the point mutation resulted in the substitution of valine byaspartic acid (p.Val559Asp) in the juxtamembrane domain of the protein. Imatinib mesylate,a therapeutic agent for canine mast cell tumors, was used to treat both tumors. Completeremission was achieved at 33 and 14 days after administration, respectively. However, inboth cases, the therapeutic response subsequently tapered with the duration of remissionlasting 66 and 255 days, respectively. Although these 2 novel c-KITmutations in exon 11 were not confirmed to be gain-of-function mutations, a further studymay help clarify relevance between mutations identified in this report andresponsiveness.

【 授权许可】

Unknown